0 NASDAQ Companies - October 19, 2020Mereo BioPharma Announces FDA Clearance to Proceed into a Phase 1b/2 study for Etigilimab (Anti-TIGIT)Bay Street NewsRead More
0 NASDAQ Companies - October 19, 2020Mereo BioPharma Announces FDA Clearance to Proceed into a Phase 1b/2 study for Etigilimab (Anti-TIGIT)Bay Street NewsRead More
0 NASDAQ Companies - October 19, 2020Mereo BioPharma Announces FDA Clearance to Proceed into a Phase 1b/2 study for Etigilimab (Anti-TIGIT)Bay Street NewsRead More
0 NASDAQ Companies - October 19, 2020Mereo BioPharma Announces FDA Clearance to Proceed into a Phase 1b/2 study for Etigilimab (Anti-TIGIT)Bay Street NewsRead More
0 NASDAQ Companies - October 19, 2020Mereo BioPharma Announces FDA Clearance to Proceed into a Phase 1b/2 study for Etigilimab (Anti-TIGIT)Bay Street NewsRead More
0 NASDAQ Companies - October 19, 2020Apellis Announces 18-Month Data from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy (GA)Bay Street NewsRead More
0 NASDAQ Companies - October 19, 2020Apellis Announces 18-Month Data from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy (GA)Bay Street NewsRead More
0 NASDAQ Companies - October 19, 2020Apellis Announces 18-Month Data from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy (GA)Bay Street NewsRead More
0 NASDAQ Companies - October 19, 2020Apellis Announces 18-Month Data from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy (GA)Bay Street NewsRead More
0 NASDAQ Companies - October 19, 2020Apellis Announces 18-Month Data from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy (GA)Bay Street NewsRead More
